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a  b  s  t  r  a  c  t
Bexsero,  a new  vaccine  against  serogroup  B meningococcal  disease  (MenB),  was  licensed  in Europe  in
January 2013.  In  Germany,  Bexsero  is recommended  for persons  at increased  risk  of  invasive  meningo-
coccal  disease,  but  not  for  universal  childhood  vaccination.  To  support  decision  making  we adapted  the
independently  developed  model  for England  to the German  setting  to predict  the potential  health  impact
and  cost-effectiveness  of  universal  vaccination  with  Bexsero® against  MenB  disease.  We  used  both  cohort
and  transmission  dynamic  mathematical  models,  the  latter  allowing  for herd  effects,  to consider  the
impact  of vaccination  on individuals  aged  0–99 years.  Vaccination  strategies  included  infant  and  adoles-
cent  vaccination,  alone  or in combination,  and  with  one-off  catch-up  programmes.  German  speciﬁc  data
were  used  where  possible  from  routine  surveillance  data  and  the  literature.  We  assessed  the impact  of
vaccination  through  cases  averted  and  quality  adjusted  life years  (QALY)  gained  and  calculated  costs  per
QALY  gained.  Assuming  65% vaccine  uptake  and  82%  strain  coverage,  infant  vaccination  was  estimated  to
prevent  15%  (34)  of MenB  cases  over the  lifetime  of one  birth  cohort.  Including  herd  effects  from  vaccina-
tion  increased  the cases  averted  by  infant  vaccination  to  22%, with  an estimated  8461  infants  requiring
vaccination  to  prevent  one  case.  In the  short  term  the greatest  health  beneﬁt  is achieved  through  routine
infant  vaccination  with  large-scale  catch-up,  which  could  reduce  cases  by 24.9%  after  5  years  and  27.9%
after  10 years.  In the  long  term  (20+  years)  policies  including  routine  adolescent  vaccination  are  most
favourable  if herd  effects  are  assumed.  Under  base  case  assumptions  with  a  vaccine  list price  of  D  96.96
the  incremental  cost-effectiveness  ratio  (ICER)  was  >D 500,000  per  QALY  for all  considered  strategies.
Given  the current  very  low  incidence  of  MenB  disease  in Germany,  universal  vaccination  with  Bexsero®
would  prevent  only  a small  absolute  number  of  cases,  at a high  overall  cost.
©  2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
In Germany, an average of 243 cases and 20 deaths of inva-
sive meningococcal disease (IMD) due to serogroup B (MenB)
were reported to the Robert Koch Institute (RKI) each year
between 2009 and 2012 (statutory surveillance data, RKI, personal
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communication). Over this period MenB accounted for 68.5% of
IMD  cases; 22% were due to MenC, 5.2% due to MenY, 3.4% due
to MenW and the remainder due to groups A, Z and 29E. While
most people recover, the disease can leave survivors with a range
of disabling sequelae, from deafness to amputation [1]. As in other
European countries, annual IMD  incidence has decreased markedly
in Germany, with MenB IMD  decreasing from a mean of 0.49 to
0.30 cases/100,000 inhabitants from 2002–2005 to 2009–2012, and
MenC IMD  from 0.18 to 0.11 cases/100,000 inhabitants [2]. The
decrease in MenC disease was disproportionately greater than for
MenB disease due to the introduction of MenC vaccine for one-year
old children in 2006 [3,4]. Quadrivalent MenACWY vaccination is
not recommended as part of the routine vaccination programme
http://dx.doi.org/10.1016/j.vaccine.2016.04.004
0264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Vaccination strategies against group B meningococcal disease modelled with base case vaccination parameters.a
Routine vaccination Months protectionb One-off catch-upc Months protection
Routine infant/toddler strategies
2,  3, 4, +12 months [18, 36] –
2,  3, 4, +12 months [18, 36] 1–4 years (0, 2 schedule) [60]
2,  3, 4, +12 months [18, 36] 1–4 years (0, 2 schedule)
5–17 years (0, 2 schedule)
[60]
2,  4, 6 +12 months [18, 36] –
2,  4, 6 +12 months [18, 36] 1–4 years (0, 2 schedule)
5–17 years (0, 2 schedule)
[60]
6,  8, 12 months [36] –
6,  8, 12 months [36] 1–4 years (0, 2 schedule)
5–17 years (0, 2 schedule)
[60]
Routine infant/toddler plus adolescent strategies
2,  3, 4, +12 months and
12 year olds (0, 2 schedule)
[18, 36]
[60]
6,  8, 12 months and
12 year olds (0, 2 schedule)
[36]
[60]
Routine adolescent strategies alone
12 year olds (0, 2 schedule) [60]
12 year olds (0, 2 schedule) [60] 13–17 years (0, 2 schedule) [60]
a Strategies involving routine adolescent vaccination were implemented in the dynamic model only.
b Waning protection from vaccination was implemented as a rate equal to 1/months protection. Where two values are speciﬁed this is the duration of protection following
the  priming course and then the booster, for example there is waning protection following the 3 dose course at 2, 3, 4 months at a monthly rate of 1/18 and following the
booster  at 12 months there is waning protection at a monthly rate of 1/36.
c For one-off catch-up campaigns the months of administration are provided to indicate the dosing schedule e.g. 1–4 years: 0, 2 indicates 2 vaccine doses given 2 months
apart  in children aged 1–4 years.
in Germany, but is recommended for those at increased risk after
individual risk assessment, such as household contacts of cases,
laboratory workers and immunocompromised persons [5].
In January 2013 Bexsero® became the ﬁrst vaccine to be licensed
in the EU to provide broad protection against MenB disease. This
vaccine is based upon a number of surface proteins and an outer
membrane vesicle component, and is thus potentially immuno-
genic against strains with sufﬁcient expression of the vaccine
antigens regardless of the capsular group [6]. In Germany the Stand-
ing Committee on Vaccination (Ständige Impfkommission, STIKO)
is the independent advisory group whose recommendations are
required for inclusion of a vaccine in the national vaccination
schedule and for reimbursement by statutory health insurance.
Currently STIKO recommends Bexsero® for persons at increased
risk of acquiring IMD, but not for universal childhood vaccination
[7]. Modelling the potential impact of a new vaccine on disease
burden provides valuable evidence to STIKO and while assessment
of the cost-effectiveness of a new vaccine is not obligatory for
development of a STIKO recommendation, results are valuable for
deciding on an overall immunisation strategy.
To support decision making in Germany we adapted the inde-
pendently developed model for England [8] to the German setting
to predict the potential health impact and cost-effectiveness of
universal vaccination with Bexsero® against MenB disease.
2. Methods
2.1. Models
We  used two models to estimate the potential impact of univer-
sal Bexsero® vaccination in Germany due to the uncertainty about
the effect of the vaccine on carriage [9]: a cohort model allowing for
direct vaccine protection against disease only, and a dynamic trans-
mission model that includes additional vaccine protection against
carriage. These models are described fully elsewhere [8]. Due to
existent universal MenC vaccination in Germany and an extremely
low incidence of meningococcal disease due to non-B serogroups
(0.15 cases per 100,000 from 2009 to 2012), we considered MenB
disease exclusively in the models.
Both models are age-structured with yearly age classes; indi-
viduals are born susceptible. Upon disease, quality of life losses
for the acute episode were included. Following disease, individuals
have three possible outcomes: survival without sequelae, survival
with sequelae (with a reduced quality of life) or death. Those dying
from the disease are assumed to lose the average life expectancy for
the age at which they die. Individuals may  die from other causes;
published mortality rates were adjusted to remove deaths due to
meningococcal disease as these are explicitly modelled. Vaccine
induced protection was assumed to start one month after the sec-
ond vaccine dose and we  allowed for waning protection (modelled
as a constant rate set to the reciprocal of the average duration
of vaccine protection). We  considered several vaccination strate-
gies (Table 1), comparing these to no universal vaccination against
MenB and treating cases as they arise, over a 100 year time horizon.
2.1.1. Cohort model speciﬁc details
A Markov model with monthly cycles was used (Appendix).
Disease cases were generated through applying the age-speciﬁc
probability of disease to the susceptible population; survivors of
disease were removed from the susceptible pool. Years of life were
weighted by the age-speciﬁc quality of life. Cohort sizes were based
upon 2011 population statistics. Single birth cohorts were con-
sidered for routine infant or toddler vaccination; multiple cohorts
were considered for strategies with catch-up vaccination.
2.1.2. Dynamic model speciﬁc details
Transmission of meningococcal carriage was represented
using a Susceptible-Infected-Susceptible (SIS) model [10] with-
out considering co-infection [11] and using a daily time step
(Appendix). Disease cases were generated by applying an age-
speciﬁc case:carrier ratio to the number of new carriage
acquisitions. Vaccinated individuals with immunity could have
protection against carriage acquisition (initially assumed to be 30%
reduction in carriage acquisition) as well as disease.
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Table 2
Epidemiological impact and cost-effectiveness of Bexsero vaccination against MenB disease in Germany assuming direct vaccine protection only, estimated using a cohort
model.
Scenario description Undiscounted Costs/beneﬁts
discounted at 3.0%
Cohorts
included
Cases averted
(%)
Cases with
sequelae
averted
Deaths
averted
Life Years
Saved
QALYs
gained
Net cost of
vaccination
(D M)
Cost(D )/QALY
gained
(D 96.96/dose)
2, 3, 4 and 12 months 1 34 (15) 4 3 239 235 191.1a 2,015,300
2,  3, 4 and 12 months with 2
dose catch-up in 1–4 years
5 63 (7) 7 5 425 420 364.1 2,154,800
2,  3, 4 and 12 months with 2
dose catch-up in 1–17 years
18 145 (6) 16 10 715 726 971.2 3,228,000
2,  4, 6 and 12 months 1 32 (14) 4 3 231 227 191.0 2,089,700
2,  4, 6 and 12 months with 2
dose catch-up in 1–17 years
18 143 (6) 16 10 707 718 971.2 3,264,500
6,  8, 12 months 1 25 (11) 3 2 186 182 143.1 1,963,100
6,  8, 12 months with 2 dose
catch-up in 1–17 years
18 137 (5) 15 9 662 673 923.3 3,309,900
a For a single birth cohort, without vaccination against MenB the cost of treating and caring for the estimated 224 cases that would occur over the lifetime of the cohort is
D  5.1 M;  vaccinating the birth cohort would cost an estimated D 191.9 M and would result in an estimated D 873,500 in healthcare savings.
2.2. Model parameters
Details of the data sources used to estimate parameters are
summarised below with full details provided in Appendix.
National surveillance data from RKI were used to estimate age-
speciﬁc disease incidence (data from 2009 to 2012) and case fatality
(2002 to 2012) for MenB disease; the longer time period was used
for case fatality due to the small annual number of meningococcal
deaths. For the dynamic model MenB carriage prevalence estimates
were based on a systematic review of all serogroup carriage com-
bined with serogroup speciﬁc information from a carriage study in
Germany [12].
Each case was  assumed to be hospitalised, with 48% requir-
ing ambulance transfer. The proportion of survivors with mild and
severe sequelae was estimated from the literature [13–17,1]. Qual-
ity of life losses for survivors with sequelae were based on currently
unpublished data from the MOSAIC study, a case–control study of
MenB survivors in the UK [1]; losses for carers of a person with
sequelae were also considered [18].
Acute health care costs included the cost of: ambulance transfer;
hospitalisation; hearing assessment; and public health manage-
ment. Costs due to loss of work were also included. The costs
of aftercare included one follow-up appointment for those aged
under 5 years, cochlear implants (0.4% of survivors), scarring treat-
ment (4%), physical therapy (1.9%) and logopaedics treatment
(3.7% of survivors under 19 years) for the year following illness.
Annual support costs were included for mild sequelae (unilateral
hearing loss) and severe sequelae (which included amputations,
major [bilateral] hearing loss, and epilepsy). We  assumed that
all cases with an amputation would result in a 50% work loss
over their lifetime, either for a parent or for themselves at a later
time.
We considered several vaccination strategies including routine
infant immunisation at varying ages with or without a catch-up
campaign (Table 1). In the dynamic model we investigated routine
adolescent vaccination (12 year olds) alone, or in combination with
an infant programme. Vaccination uptake was estimated based on
the uptake of other vaccines with similar age-speciﬁc schedules in
current use. Vaccine strain coverage was estimated using results of
the Meningococcal antigen typing system (MATS) assay on German
strains [6,19]. The 2015 pharmacy retail price of D 96.96 was used
as the cost per vaccine dose. Costs of vaccine administration were
estimated from administration costs for other vaccines in Germany.
We included the costs of hospitalisation for severe fever and ana-
phylaxis as possible adverse events following vaccination, but did
not include possible quality of life losses associated with adverse
events, which were assumed to resolve quickly.
2.3. Effectiveness analyses
We  calculated the number needed to vaccinate (NNV) to pre-
vent one case by dividing the number of persons vaccinated by the
number of cases averted under various model assumptions.
2.4. Cost-effectiveness analyses
Health outcomes were deﬁned as cases averted, deaths averted
and quality adjusted life years (QALYs) gained under vaccination.
All costs were measured in Euros at 2013 prices, with previous costs
adjusted based on the German consumer price index [20]. In the
base case, future costs and beneﬁts were discounted back to their
present value at a rate of 3.0% as recommended in Germany [21]
and the analysis was  undertaken from the payer perspective.
2.5. Scenario analyses
Parameter uncertainty was handled through scenario analyses
and by probabilistic sensitivity analyses (PSA). Factors considered
in scenario analyses included: disease incidence, population mix-
ing, vaccination uptake, strain coverage, vaccine price, societal
perspective (with and without the addition of quality of life losses
for carers and costs for work loss) and discount rates. The PSA was
used to characterise the uncertainty around other model parame-
ters (Appendix).
3. Results
3.1. Health impact
3.1.1. Cohort model: direct effects (no vaccine effects on carriage)
Table 2 shows the predicted impact of vaccination in birth
cohorts (663,026 individuals in a single birth cohort) over their life-
time. In the absence of MenB vaccination the model estimates 224
cases of MenB disease and 19 deaths would occur over a cohort’s
lifetime. Assuming 65% vaccine uptake and 82% strain coverage,
vaccinating infants with a 2, 3, 4 + 12 months schedule is estimated
to avert 34 (15%) of these cases and 3 deaths, with a similar number
prevented under a 2, 4, 6 + 12 months programme (Fig. 1). Vacci-
nation at 6, 8, 12 months of age averted 25 cases as the assumed
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Fig. 1. Predicted cumulative cases by year over the lifetime of a single birth cohort under different vaccination scenarios.
Fig. 2. Results of 1000 Monte Carlo simulation predictions of difference vaccination strategies presented on the cost-effectiveness plane.
increased duration of protection does not compensate for miss-
ing the cases that occur before vaccination. To consider catch-up
strategies additional birth cohorts are included. Adding a large
one-off catch-up strategy for 1–17 year olds to the routine infant
schedule averted more cases. However, the percentage averted is
reduced (from 15% to 6%) because incidence and assumed vaccine
uptake are lower in 1–17 year olds compared to under one-year
olds.
3.1.2. Dynamic transmission model: incorporating herd effects
following vaccination
We  assumed a 30% vaccine efﬁcacy against acquisition. When
considering routine infant vaccination alone, strategies starting
earlier in life remained most favourable in reducing cases. The
greatest health beneﬁt in the short term, however, is achieved
through routine infant vaccination with large-scale catch-up,
which could reduce cases by 24.9% after 5 years and 27.9% after 10
years (Fig. 3). In the long term (20 years or more) policies includ-
ing routine vaccination of 12 year olds are most favourable; after
50 years routine adolescent vaccination leads to an annual case
reduction of 37.9% compared to no vaccination (Fig. 3).
3.1.3. Number needed to vaccinate
Considering direct effects only (no herd protection) 12,668 chil-
dren would need to receive the vaccine to prevent a single case
over a cohort’s lifetime with a 2, 3, 4 + 12 months schedule. Assum-
ing 30% vaccine effectiveness against carriage, this reduces to 8461
children and becomes even more favourable if older children are
also vaccinated, reducing to 6373 children for the vaccination strat-
egy 6, 8, 12 months +12 years.
4. Economic impact and cost-effectiveness
At a vaccine price per dose of D 96.96 vaccination of infants at
2, 3, 4 + 12 months within the cohort model is expected to cost
D 191.9 M annually (Table 2). The predicted reduction in health-
care costs over a cohort’s lifetime as a result of direct vaccine
effects is D 873,500 with a resulting incremental cost-effectiveness
ratio (ICER) of D 2.0 M per QALY gained. Assuming direct vac-
cine effects only, all vaccination strategies considered resulted in
very high ICERs, with strategies that included catch-up being least
favourable (Table 2, Fig. 2). Allowing for herd effects improves
the cost-effectiveness of vaccination, however, the ICER remains
3416
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Table 3
Epidemiological impact and cost-effectiveness of Bexsero vaccination against MenB disease in Germany allowing for herd effects, estimated using a dynamic transmission model.
Scenario description Undiscounted Costs/beneﬁts discounted at 3.0%
Cases averted
(%)
Cases with
sequelae
averted
Deaths
averted
Life Years
Saved
QALYs gained Net cost of
vaccination
(D M)
Cost (D )/QALY
gained
(D 96.96/dose)
Cost (D )/QALY
gained
(D 60/dose)
Cost (D )/QALY
gained
(D 30/dose)
Cost (D )/QALY
gained
(D 0/dose)
Assuming 30% vaccine efﬁcacy against carriage
2, 3, 4 and 12 months 5094 (22) 557 450 20,363 23,176 18,713.8 1,391,300 918,300 534,400 150,500
2,  3, 4 and 12 months with 2
dose catch-up in 1–4 years
5192 (23) 568 458 20,856 23,739 18,877.7 1,369,600 903,500 525,100 146,800
2,  3, 4 and 12 months with 2
dose catch-up in 1–17 years
5720 (25) 627 499 23,059 26,302 19,398.6 1,257,200 827,400 478,500 129,500
2,  4, 6 and 12 months 4967 (22) 543 439 19,851 22,590 18,716.2 1,429,400 943,500 549,100 154,700
2,  4, 6 and 12 months with 2
dose catch-up in 1–17 years
5598 (25) 613 489 22,577 25,750 19,400.9 1,283,000 844,300 488,300 132,300
6,  8, 12 months 4214 (19) 460 377 16,810 19,112 14,029.0 1,280,900 845,400 491,800 138,300
6,  8, 12 months and 12 years 10,308 (45) 1134 859 32,918 38,200 20,756.6 998,900 652,600 371,600 90,500
12  years 7455 (33) 822 602 20,959 24,636 6704.9 540,800 345,500 187,000 28,500
12  years with 2 dose catch-up
in 13–17 years
7790 (34) 859 630 22,526 26,431 6902.3 520,100 332,300 179,800 27,300
Assuming 60% vaccine efﬁcacy against carriage
2, 3, 4 and 12 months 6318 (28) 692 554 24,512 27,963 18,692.9 1,160,100 765,400 445,100 124,700
2,  3, 4 and 12 months with 2
dose catch-up in 1–17 years
7386 (33) 810 639 28,987 33,158 19,368.4 982,600 646,200 373,200 100,200
2,  4, 6 and 12 months 6197 (27) 678 544 24,020 27,401 18,695.2 1,185,900 782,500 455,000 127,600
6,  8, 12 months 5494 (24) 601 485 21,132 24,102 14,007.2 1,022,200 674,300 391,800 109,400
6,  8, 12 months and 12 years 14,267 (63) 1568 1197 44,277 51,483 20,692.9 744,300 485,800 275,900 66,100
12  years 11,964 (53) 1317 990 33,825 39,649 6633.7 337,600 214,900 115,400 15,800
12  years with 2 dose catch-up
in 13–17 years
12,554 (55) 1382 1041 36,536 42,750 6825.9 322,800 205,400 110,200 15,000
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Fig. 3. Predicted annual cases of MenB disease under different vaccination scenarios, assuming herd effects (30% vaccine efﬁcacy against carriage, note the scaling of the
Y-axis).
over D 500,000 for all considered strategies (Table 3). The inclu-
sion of herd effects makes catch-up in addition to routine infant
immunisation more economically favourable than routine infant
immunisation alone. The lowest ICERs in this context are produced
by strategies with routine adolescent immunisation (Table 3), due
to the reduced dosing schedule and therefore lower costs for vacci-
nation, and consistent targeting of those with high meningococcal
carriage prevalence.
5. Sensitivity analyses
Increasing vaccine uptake in infants from 65% to 70% resulted
in an estimated 1% point increase in cases averted assuming direct
protection only or 2% point increase when including herd effects.
Increasing the strain coverage to 92% resulted in a 2% point increase
in averted cases assuming direct protection only or 3% point
increase allowing for herd effects. Allowing for lower vaccine strain
coverage in infants compared to older age groups (<1 year 68%; 1–9
years 88%; 10–19 years 86%; 20–49 years 79%; 50+ years 76%, see
Appendix) reduced the estimated cases directly averted from 34 to
32 over the cohort’s lifetime. Altering the assumption about pop-
ulation mixing to one based on self-reported contacts in Germany
rather than a simple structure also reduced the proportion of pre-
dicted cases averted through vaccination from 22% to 19% in the
dynamic model (Appendix). Both models were also sensitive to dis-
ease incidence (Appendix). ICERs remained very high even when
using vaccine favourable assumptions or allowing for herd effects.
From the societal perspective ICERs were lower, but remained over
one million Euros per QALY gained even when allowing for herd
effects (Appendix). Reducing the cost of the vaccine considerably
reduced the ICER, however the cost per QALY gained remained over
D 100,000 even with a vaccine price of D 0 and including herd effects
(up to 60% efﬁcacy against carriage acquisition) for the infant strate-
gies. Routine adolescent vaccination strategies assuming indirect
protection were more economically favourable, but the vaccine
would have to be priced at less than D 1 a dose for the ICER to
fall below D 30,000 per QALY gained. Of the parameters consid-
ered probabilistically in the cohort model, the incremental costs
of vaccination were most sensitive to the vaccine administration
costs and the rates of adverse vaccine reactions; incremental QALYs
gained were most sensitive to the quality of life loss utilities and to
a lesser extent the proportion of people with sequelae associated
with disease and long-term sequelae (Appendix).
6. Discussion
6.1. Principal ﬁndings
Model predictions suggest that only a small proportion and low
absolute number of MenB cases could be prevented each year in
Germany if Bexsero® vaccination was  introduced at 2, 3, 4 + 12
months and if the vaccine had no impact on carriage. This low
absolute impact is due to the very low MenB incidence and only
moderate anticipated vaccination uptake in Germany. Delaying the
age at which the vaccine course is started reduces the potential
health impact because young infants are at greatest risk of disease.
The limited impact of MenB vaccination in the German setting is
also reﬂected in very high NNVs. High NNVs (over 30,000) were
also estimated for MenB infant vaccination in Canada [22]. For
comparison, much lower NNVs have been estimated to prevent
one inﬂuenza-related hospitalisation when vaccinating children
aged 6–23 months with an inﬂuenza vaccine at 50% efﬁcacy (NNV
1031–3050) [23] and an estimated 80 children would need to
receive rotavirus vaccination to prevent one hospitalisation [24].
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In terms of economic impact, all modelled strategies for the use of
Bexsero® vaccination in Germany were associated with ICERs over
D 500,000 per QALY gained under base case conditions. This was
driven by the low absolute number of preventable cases predicted,
particularly by the models that assumed no herd effects, however,
evidence for an impact on carriage is uncertain [25,26].
6.2. Strengths and limitations
Our models use the latest available German speciﬁc data where
possible and the use of a transmission dynamic model allows for
indirect vaccine beneﬁts (herd effects). Both payer and societal per-
spectives were explored. There is considerable uncertainty in some
of the parameters used in the models and this was addressed using
a partial probabilistic approach in the cohort model and scenario
analyses in both models.
The models here consider MenB disease only, as we considered
the impact on other serogroups would be very limited given their
low incidence (there were only 42, 6 and 7 cases annually of MenC,
W and Y, respectively in under 20 year olds from 2009 to 2012) and
MenC vaccination coverage in targeted cohorts is already very high
[27]. There were limited available data on the incidence and costs
associated with long term sequelae in Germany. Consequently, we
did not include long-term costs for mild learning disability or insti-
tutional care for patients with severe disability, making our cost
estimate for severe sequelae rather conservative [8,28–32]. We
did include costs for rehabilitation, physical therapy, and speech
therapy in the year after illness for a proportion of the patients.
Not including the full range and costs of possible sequelae from
meningococcal disease will have increased the estimated cost per
QALY gained of the vaccination strategies, however in sensitivity
analyses ICERs remained high even when the proportion of patients
with sequelae and their associated costs were increased. In other
aspects the model parameters were potentially vaccine favourable.
For instance, we did not include quality of life losses from adverse
vaccine reactions, allowances for strain replacement or poten-
tial deleterious effects of reducing meningococcal transmission. In
addition, duration of protection in scenarios that included catch-up
vaccination of toddlers may  be overoptimistic based on a recently
published small study of hSBA persistence [33].
6.3. Comparison with other studies
Modelling and cost-effectiveness studies on the use of Bexsero®
have been published for England [8,34], the Netherlands [30],
France [35], Belgium [32] and Canada [29]. In Spain the direct health
impact alone was considered [36]. As for the German models pre-
sented here, the England and Belgian analyses included the use of
dynamic transmission models to appropriately allow for any herd
effects. In France herd effects were estimated through incorpora-
tion into a Markov model and direct protection was  principally
considered in the Dutch and the Canadian studies primarily due
to limited evidence of the effect of Bexsero® on meningococcal
carriage and transmission. The predictions here for vaccination in
Germany are in line with those estimated elsewhere, namely that
in the absence of herd effects routine immunisation early in life
offers the greatest health impact, but with the inclusion of herd
effects routine immunisation of teenagers becomes the best long-
term strategy. Although the ICERs under base case conditions have
been found to be high in all countries considered thus far, those
presented for Germany are amongst the highest to date. This is
in part explained by a higher vaccine price, the lower sequelae
costs assigned to MenB patients as well as the very low MenB inci-
dence (lower only in the Canadian model that also estimated high
ICERs > $CDN 3 Million for infant vaccination).
6.4. Implications for policy makers
Our models suggest that maximal health impact in the short
term could be achieved in Germany by vaccinating infants early
in life. However, a recent study of paediatricians in Germany sug-
gested only 13.4% of physicians preferred this strategy, in contrast
to the 66.7% who preferred vaccination at 6, 8, 12 months (14%
chose neither schedule) [37]. Paediatricians were concerned about
acceptance and safety of concomitant vaccination and possible
parental refusal of other recommended vaccines since vaccinating
MenB early in life would usually involve three vaccine shots per
appointment. Thus, any immunisation decision will need to balance
the potential beneﬁts of any given vaccination strategy, the likeli-
hood of the strategy being adopted in practice, as well as potentially
unfavourable effects on the uptake of other vaccines.
7. Conclusions
Given the current very low incidence of MenB disease in
Germany, implementation of universal infant vaccination with
Bexsero® would prevent only a small absolute number of cases.
If the vaccine has an effect on carriage, the prevented number of
cases and deaths increase signiﬁcantly when vaccinating adoles-
cents alone or – even more – when adding adolescent vaccination
to a routine infant vaccination strategy. Whilst cost-effectiveness
is not a central requirement for immunisation decision-making
in Germany, the majority of scenarios considerably exceeded
commonly used economic willingness to pay thresholds.
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